CSL Seqirus to Present 14 Abstracts at ESWI 2025
CSL Seqirus, part of CSL (ASX: CSL), announced today that it will present 14 abstracts at the European Scientific Working group on Influenza (ESWI) conference, taking place October 20–23 in Valencia, Spain. The presentations underscore the value of enhanced seasonal influenza vaccines and reinforce their critical role in protecting public health.
“ESWI is a critical moment in time for the seasonal influenza vaccine community to come together and discuss the latest research in the infectious diseases space,” said Pepe Meseguer Perez, Spain and Iberian Cluster Head at CSL Seqirus. “Our presence at ESWI’s 10th congress is underpinned by the strength of the data we have submitted. We are excited to welcome the vaccine community to Valencia to share our results.”
Key Data Highlights and Their Public Health Implications
The abstracts cover a range of topics, including population health impact and vaccine effectiveness in older adults, a key demographic for influenza prevention strategies. Notable data highlights include analyses of enhanced influenza vaccination in adults over 65 and comparative effectiveness studies of adjuvanted and high-dose vaccines in reducing test-confirmed influenza outcomes, hospitalizations, and outcomes in high-risk groups.
One highlight, “A Public Health and Comparative Cost Analysis of Enhanced Influenza Vaccination in Adults Aged >65 years Compared to Current Programmes Across the Nordic Regions,” will be presented in the poster session on October 21. The poster number is 238, with an accompanying discussion window from 18:00 to 18:30. These data contribute to the ongoing conversation about value-based vaccination strategies for aging populations across Europe.
Another key presentation, “Comparable Vaccine Effectiveness of Adjuvanted and High-Dose Influenza Vaccines in Preventing Test-Confirmed Influenza Outcomes, including Hospitalisation, in Overall and High-Risk Older Adults: A Test-Negative Design Study During 2022–2023 and 2023–2024,” will be explored in a session on October 22. This poster, number 153, runs from 17:30 to 19:00 and adds to the evidence base supporting the use of enhanced vaccines to improve health outcomes in vulnerable groups.
Jonathan Anderson, Executive Medical Director, International Regions (Europe and Asia Pacific) at CSL Seqirus, commented on the broader significance of the data. “The data being presented at ESWI this year will highlight the clear effectiveness of enhanced seasonal influenza vaccines. These data show clearly the benefit enhanced influenza vaccines may have to public health.”
Supporting the Next Generation of Scientists
In addition to presenting data, CSL Seqirus is strengthening the scientific community’s capacity through sponsorship and education. The company sponsors the 4th Young Scientist Vaccine Innovation Award, honoring outstanding research by an emerging scientist in influenza vaccine development. The award ceremony is scheduled for 23 October, 09:30–10:30, highlighting the commitment to nurturing future leaders in influenza research.
CSL Seqirus will also host a Satellite Symposium on 21 October, 16:00–17:00, under the theme “Addressing the Evolving Influenza Landscape: A Public Health Imperative.” The symposium aims to foster dialogue on how evolving influenza landscapes shape vaccine strategy and policy, with implications for public health planning and vaccination programs worldwide.
About Seasonal Influenza and the Role of Vaccination
Seasonal influenza remains a significant public health challenge, with transmission that can occur before symptoms appear and for several days after onset. The disease contributes to substantial morbidity and mortality, particularly among older adults and those with underlying health conditions. In Europe, seasonal influenza imposes a substantial annual health burden, underscoring the importance of vaccines—especially enhanced formulations—in reducing hospitalizations and severe outcomes.
CSL Seqirus is a leading influenza vaccine provider with manufacturing facilities in the United States, the United Kingdom, and Australia. The company leverages egg, cell, and adjuvant technologies to deliver a portfolio of vaccines across more than 20 countries. CSL Seqirus collaborates with health authorities and research institutions to advance influenza prevention and pandemic preparedness.
Forward-Looking Statements and Accessibility
This release contains forward-looking statements about CSL Seqirus and its vaccine programs, which are subject to risks and uncertainties. For more information on CSL Seqirus products and ESWI abstracts, please consult CSL Seqirus communications and regional regulatory guidance.
About FLUAD, an adjuvanted influenza vaccine, is included as part of CSL Seqirus’ portfolio discussions in public materials. Full prescribing information and safety data are available through healthcare professionals and regulatory resources.
For more information about CSL Seqirus, visit CSL.com.
